References
1 Lloyd‐Jones, D, Adams, RJ, Brown, TM, Carnethon, M, Dai, S, De Simone, G, Ferguson, TB, Ford, E, Furie, K, Gillespie, C, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation 2010, 121:e46–e215.
2 Insull, W , Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med 2009, 122:S3–S14.
3 Naghavi, M, Falk, E. %22From vulnerable plaque to vulnerable patient.%22
Asymptomatic Atherosclerosis. New York, NY:
Humana Press; 2010, 13–38.
4 Sousa, JE, Serruys, PW, Costa, MA. New frontiers in cardiology: drug‐eluting stents: part I. Circulation 2003, 107:2274–2279.
5 Finn, AV, Nakazawa, G, Joner, M, Kolodgie, FD, Mont, EK, Gold, HK, Virmani, R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007, 27:1500–1510.
6 Shyy, JY, Chien, S. Role of integrins in endothelial mechanosensing of shear stress. Circ Res 2002, 91:769–775.
7 Arroyo, LH, Lee, RT. Mechanisms of plaque rupture: mechanical and biologic interactions. Cardiovasc Res 1999, 41:369–375.
8 Saam, T, Hatsukami, TS, Takaya, N, Chu, B, Underhill, H, Kerwin, WS, Cai, J, Ferguson, MS, Yuan, C. The vulnerable, or high‐risk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment. Radiology 2007, 244:64–77.
9 Van Berkel, TJ, De Rijke, YB, Kruijt, JK. Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats. Recognition by various scavenger receptors on Kupffer and endothelial liver cells. J Biol Chem 1991, 266:2282–2289.
10 Williams, KJ, Tabas, I. The response‐to‐retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551–561.
11 Tabas, I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005, 25:2255–2264.
12 Pluddemann, A, Neyen, C, Gordon, S. Macrophage scavenger receptors and host‐derived ligands. Methods 2007, 43:207–217.
13 Herman, MP, Sukhova, GK, Libby, P, Gerdes, N, Tang, N, Horton, DB, Kilbride, M, Breitbart, RE, Chun, M, Schonbeck, U. Expression of neutrophil collagenase (matrix metalloproteinase‐8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001, 104:1899–1904.
14 Johnson, C, Sung, HJ, Lessner, SM, Fini, ME, Galis, ZS. Matrix metalloproteinase‐9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res 2004, 94:262–268.
15 Gough, PJ, Gomez, IG, Wille, PT, Raines, EW. Macrophage expression of active MMP‐9 induces acute plaque disruption in apoE‐deficient mice. J Clin Invest 2006, 116:59–69.
16 Sluijter, JP, Pulskens, WP, Schoneveld, AH, Velema, E, Strijder, CF, Moll, F, de Vries, JP, Verheijen, J, Hanemaaijer, R, de Kleijn, DP, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 2006, 37:235–239.
17 de Nooijer, R, Verkleij, CJ, von der Thusen, JH, Jukema, JW, van der Wall, EE, van Berkel, TJ, Baker, AH, Biessen, EA. Lesional overexpression of matrix metalloproteinase‐9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 2006, 26:340–346.
18 Libby, P. Inflammation in atherosclerosis. Nature 2002, 420:868–874.
19 Finet, G, Ohayon, J, Rioufol, G. Biomechanical interaction between cap thickness, lipid core composition and blood pressure in vulnerable coronary plaque: impact on stability or instability. Coron Artery Dis 2004, 15:13–20.
20 Galis, ZS, Khatri, JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002, 90:251–262.
21 Galis, ZS, Sukhova, GK, Lark, MW, Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493–2503.
22 Lee, RT, Grodzinsky, AJ, Frank, EH, Kamm, RD, Schoen, FJ. Structure‐dependent dynamic mechanical behavior of fibrous caps from human atherosclerotic plaques. Circulation 1991, 83:1764–1770.
23 Beaussier, H, Masson, I, Collin, C, Bozec, E, Laloux, B, Calvet, D, Zidi, M, Boutouyrie, P, Laurent, S. Carotid plaque, arterial stiffness gradient, and remodeling in hypertension. Hypertension 2008, 52:729–736.
24 Tajaddini, A, Kilpatrick, DL, Vince, DG. A novel experimental method to estimate stress‐strain behavior of intact coronary arteries using intravascular ultrasound (IVUS). J Biomech Eng 2003, 125:120–123.
25 Kim, YS, Galis, ZS, Rachev, A, Han, HC, Vito, RP. Matrix metalloproteinase‐2 and ‐9 are associated with high stresses predicted using a nonlinear heterogeneous model of arteries. J Biomech Eng 2009, 131:011009.
26 Cheng, C, Tempel, D, van Haperen, R, van der Baan, A, Grosveld, F, Daemen, MJ, Krams, R, de Crom, R. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 2006, 113:2744–2753.
27 Douma, K, Prinzen, L, Slaaf, DW, Reutelingsperger, CP, Biessen, EA, Hackeng, TM, Post, MJ, van Zandvoort, MA. Nanoparticles for optical molecular imaging of atherosclerosis. Small 2009, 5:544–557.
28 Trivedi, RA, Mallawarachi, C, UK‐I, JM, Graves, MJ, Horsley, J, Goddard, MJ, Brown, A, Wang, L, Kirkpatrick, PJ, Brown, J, et al. Identifying inflamed carotid plaques using in vivo USPIO‐enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol 2006, 26:1601–1606.
29 Holzapfel, GA, Sommer, G, Regitnig, P. Anisotropic mechanical properties of tissue components in human atherosclerotic plaques. J Biomech Eng 2004, 126:657–665.
30 Richardson, PD. Biomechanics of plaque rupture: progress, problems, and new frontiers. Ann Biomed Eng 2002, 30:524–536.
31 Little, WC, Constantinescu, M, Applegate, RJ, Kutcher, MA, Burrows, MT, Kahl, FR, Santamore, WP. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild‐to‐moderate coronary artery disease? Circulation 1988, 78:1157–1166.
32 Giroud, D, Li, JM, Urban, P, Meier, B, Rutishauer, W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992, 69:729–732.
33 Cutlip, DE, Chhabra, AG, Baim, DS, Chauhan, MS, Marulkar, S, Massaro, J, Bakhai, A, Cohen, DJ, Kuntz, RE, Ho, KK. Beyond restenosis: five‐year clinical outcomes from second‐generation coronary stent trials. Circulation 2004, 110:1226–1230.
34 Glaser, R, Selzer, F, Faxon, DP, Laskey, WK, Cohen, HA, Slater, J, Detre, KM, Wilensky, RL. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 2005, 111:143–149.
35 de Weert, TT, Ouhlous, M, Meijering, E, Zondervan, PE, Hendriks, JM, van Sambeek, MR, Dippel, DW, van der Lugt, A. In vivo characterization and quantification of atherosclerotic carotid plaque components with multidetector computed tomography and histopathological correlation. Arterioscler Thromb Vasc Biol 2006, 26:2366–2372.
36 Das, M, Braunschweig, T, Muhlenbruch, G, Mahnken, AH, Krings, T, Langer, S, Koeppel, T, Jacobs, M, Gunther, RW, Mommertz, G. Carotid plaque analysis: comparison of dual‐source computed tomography (CT) findings and histopathological correlation. Eur J Vasc Endovasc Surg 2009, 38:14–19.
37 Cai, J, Hatsukami, TS, Ferguson, MS, Kerwin, WS, Saam, T, Chu, B, Takaya, N, Polissar, NL, Yuan, C. In vivo quantitative measurement of intact fibrous cap and lipid‐rich necrotic core size in atherosclerotic carotid plaque: comparison of high‐resolution, contrast‐enhanced magnetic resonance imaging and histology. Circulation 2005, 112:3437–3444.
38 Beduneau, A, Ma, Z, Grotepas, CB, Kabanov, A, Rabinow, BE, Gong, N, Mosley, RL, Dou, H, Boska, MD, Gendelman, HE. Facilitated monocyte‐macrophage uptake and tissue distribution of superparmagnetic iron‐oxide nanoparticles. PLoS One 2009, 4:e4343.
39 Briley‐Saebo, KC, Johansson, LO, Hustvedt, SO, Haldorsen, AG, Bjornerud, A, Fayad, ZA, Ahlstrom, HK. Clearance of iron oxide particles in rat liver—effect of hydrated particle size and coating material on liver metabolism. Invest Radiol 2006, 41:560–571.
40 Briley‐Saebo, KC, Mani, V, Hyafil, F, Cornily, JC, Fayad, ZA. Fractionated feridex and positive contrast: in vivo MR imaging of atherosclerosis. Magn Reson Med 2008, 59:721–730.
41 Tang, TY, Muller, KH, Graves, MJ, Li, ZY, Walsh, SR, Young, V, Sadat, U, Howarth, SP, Gillard, JH. Iron oxide particles for atheroma imaging. Arterioscler Thromb Vasc Biol 2009, 29:1001–1008.
42 Thomsen, HS. Gadolinium‐based contrast media may be nephrotoxic even at approved doses. Eur Radiol 2004, 14:1654–1656.
43 Bastus, NG, Sanchez‐Tillo, E, Pujals, S, Farrera, C, Lopez, C, Giralt, E, Celada, A, Lloberas, J, Puntes, V. Homogeneous conjugation of peptides onto gold nanoparticles enhances macrophage response. ACS Nano 2009, 3:1335–1344.
44 Simberg, D, Park, JH, Karmali, PP, Zhang, WM, Merkulov, S, McCrae, K, Bhatia, SN, Sailor, M, Ruoslahti, E. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials 2009, 30:3926–3933.
45 Fujimoto, S, Hartung, D, Ohshima, S, Edwards, DS, Zhou, J, Yalamanchili, P, Azure, M, Fujimoto, A, Isobe, S, Matsumoto, Y, et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am Coll Cardiol 2008, 52:1847–1857.
46 Kooi, ME, Cappendijk, VC, Cleutjens, KB, Kessels, AG, Kitslaar, PJ, Borgers, M, Frederik, PM, Daemen, MJ, van Engelshoven, JM. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003, 107:2453–2458.
47 Lipinski, MJ, Frias, JC, Amirbekian, V, Briley‐Saebo, KC, Mani, V, Samber, D, Abbate, A, Aguinaldo, JG, Massey, D, Fuster, V, et al. Macrophage‐specific lipid‐based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc Imaging 2009, 2:637–647.
48 Nahrendorf, M, Zhang, H, Hembrador, S, Panizzi, P, Sosnovik, DE, Aikawa, E, Libby, P, Swirski, FK, Weissleder, R. Nanoparticle PET‐CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008, 117:379–387.
49 Trivedi, RA, UK‐I, JM, Graves, MJ, Kirkpatrick, PJ, Gillard, JH. Noninvasive imaging of carotid plaque inflammation. Neurology 2004, 63:187–188.
50 Waldo, SW, Li, Y, Buono, C, Zhao, B, Billings, EM, Chang, J, Kruth, HS. Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol 2008, 172:1112–1126.
51 Raynal, I, Prigent, P, Peyramaure, S, Najid, A, Rebuzzi, C, Corot, C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran‐10. Invest Radiol 2004, 39:56–63.
52 Sanz, J, Fayad, ZA. Imaging of atherosclerotic cardiovascular disease. Nature 2008, 451:953–957.
53 Moreno, PR, Purushothaman, KR, Fuster, V, Echeverri, D, Truszczynska, H, Sharma, SK, Badimon, JJ, O`Connor, WN. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004, 110:2032–2038.
54 Giannarelli, C, Ibanez, B, Cimmino, G, Garcia Ruiz, JM, Faita, F, Bianchini, E, Zafar, MU, Fuster, V, Garcia, MJ, Badimon, JJ. Contrast‐enhanced ultrasound imaging detects intraplaque neovascularization in an experimental model of atherosclerosis. JACC Cardiovasc Imaging 2010, 3:1256–1264.
55 Manca, C, Parenti, G, Bellina, R, Boni, G, Grosso, M, Bernini, W, Palombo, C, Paterni, M, Pelosi, G, Lanza, M, et al. In‐111 platelet scintigraphy for the noninvasive detection of carotid plaque thrombosis. Stroke 2001, 32:719–727.
56 Annovazzi, A, Bonanno, E, Arca, M, D`Alessandria, C, Marcoccia, A, Spagnoli, LG, Violi, F, Scopinaro, F, De Toma, G, Signore, A. 99mTc‐interleukin‐2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. Eur J Nucl Med Mol Imaging 2006, 33:117–126.
57 Tawakol, A, Migrino, RQ, Bashian, GG, Bedri, S, Vermylen, D, Cury, RC, Yates, D, LaMuraglia, GM, Furie, K, Houser, S, et al. In vivo 18F‐fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006, 48:1818–1824.
58 Burke, AP, Farb, A, Malcom, GT, Liang, YH, Smialek, J, Virmani, R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997, 336:1276–1282.
59 Yamagishi, M, Terashima, M, Awano, K, Kijima, M, Nakatani, S, Daikoku, S, Ito, K, Yasumura, Y, Miyatake, K. Morphology of vulnerable coronary plaque: insights from follow‐up of patients examined by intravascular ultrasound before an acute coronary syndrome. J Am Coll Cardiol 2000, 35:106–111.
60 Bayturan, O, Tuzcu, EM, Nicholls, SJ, Balog, C, Lavoie, A, Uno, K, Crowe, TD, Magyar, WA, Wolski, K, Kapadia, S, et al. Attenuated plaque at nonculprit lesions in patients enrolled in intravascular ultrasound atherosclerosis progression trials. JACC Cardiovasc Interv 2009, 2:672–678.
61 Lee, SY, Mintz, GS, Kim, SY, Hong, YJ, Kim, SW, Okabe, T, Pichard, AD, Satler, LF, Kent, KM, Suddath, WO, et al. Attenuated plaque detected by intravascular ultrasound: clinical, angiographic, and morphologic features and post‐percutaneous coronary intervention complications in patients with acute coronary syndromes. JACC Cardiovasc Interv 2009, 2:65–72.
62 Nair, A, Kuban, BD, Tuzcu, EM, Schoenhagen, P, Nissen, SE, Vince, DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002, 106:2200–2206.
63 Van Herck, J, De Meyer, G, Ennekens, G, Van Herck, P, Herman, A, Vrints, C. Validation of in vivo plaque characterisation by virtual histology in a rabbit model of atherosclerosis. EuroIntervention 2009, 5:149–156.
64 Rodriguez‐Granillo, GA, Garcia‐Garcia, HM, Mc Fadden, EP, Valgimigli, M, Aoki, J, de Feyter, P, Serruys, PW. In vivo intravascular ultrasound‐derived thin‐cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol 2005, 46:2038–2042.
65 Serruys, PW. Fourth annual American College of Cardiology international lecture: a journey in the interventional field. J Am Coll Cardiol 2006, 47:1754–1768.
66 Stone, GW, Maehara, A, Lansky, AJ, de Bruyne, B, Cristea, E, Mintz, GS, Mehran, R, McPherson, J, Farhat, N, Marso, SP, et al. A prospective natural‐history study of coronary atherosclerosis. New Engl J Med 2011, 364:226–235.
67 Low, AF, Tearney, GJ, Bouma, BE, Jang, IK. Technology Insight: optical coherence tomography–current status and future development. Nat Clin Pract Cardiovasc Med 2006, 3:154–162, quiz 172.
68 Stamper, D, Weissman, NJ, Brezinski, M. Plaque characterization with optical coherence tomography. J Am Coll Cardiol 2006, 47:C69–C79.
69 Templin, C, Meyer, M, Muller, MF, Djonov, V, Hlushchuk, R, Dimova, I, Flueckiger, S, Kronen, P, Sidler, M, Klein, K, et al. Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy. Eur Heart J 2010, 31:1792–1801.
70 Fuster, V, Fayad, ZA, Moreno, PR, Poon, M, Corti, R, Badimon, JJ. Atherothrombosis and high‐risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol 2005, 46:1209–1218.
71 Fuster, V, Corti, R, Fayad, ZA, Schwitter, J, Badimon, JJ. Integration of vascular biology and magnetic resonance imaging in the understanding of atherothrombosis and acute coronary syndromes. J Thromb Haemost 2003, 1:1410–1421.
72 Sirol, M, Fuster, V, Fayad, ZA. Plaque imaging and characterization using magnetic resonance imaging: towards molecular assessment. Curr Mol Med 2006, 6:541–548.
73 Moreno, PR. Vulnerable plaque: definition, diagnosis, and treatment. Cardiol Clin 2010, 28:1–30.
74 Sathyanarayana, S, Schar, M, Kraitchman, DL, Bottomley, PA. Towards real‐time intravascular endoscopic magnetic resonance imaging. JACC Cardiovasc Imaging 2010, 3:1158–1165.
75 Hirsch, LR, Stafford, RJ, Bankson, JA, Sershen, SR, Rivera, B, Price, RE, Hazle, JD, Halas, NJ, West, JL. Nanoshell‐mediated near‐infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A 2003, 100:13549–13554.
76 Luker, GD, Luker, KE. Optical imaging: current applications and future directions. J Nucl Med 2008, 49:1–4.
77 Goldstein, JA, Grines, C, Fischell, T, Virmani, R, Rizik, D, Muller, J, Dixon, SR. Coronary embolization following balloon dilation of lipid‐core plaques. JACC Cardiovasc imaging 2009, 2:1420–1424.
78 Madden, SP, Sum, ST, Muller, JE. %22Assessment of coronary stenosis with near infrared spectroscopy.%22 In: Escaned, J, Serruys, P, eds. Coronary Stenosis Imaging, Structure, and Physiology. Toulouse:
PCR Publishing; 2010.
79 Caplan, JD, Waxman, S, Nesto, RW, Muller, JE. Near‐infrared spectroscopy for the detection of vulnerable coronary artery plaques. J Am Coll Cardiol 2006, 47:C92–C96.
80 Gardner, CM, Tan, H, Hull, EL, Lisauskas, JB, Sum, ST, Meese, TM, Jiang, C, Madden, SP, Caplan, JD, Burke, AP, et al. Detection of lipid core coronary plaques in autopsy specimens with a novel catheter‐based near‐infrared spectroscopy system. JACC Cardiovasc Imaging 2008, 1:638–648.
81 Moreno, PR, Lodder, RA, Purushothaman, KR, Charash, WE, O`Connor, WN, Muller, JE. Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near‐infrared spectroscopy. Circulation 2002, 105:923–927.
82 Schultz, CJ, Serruys, PW, van der Ent, M, Ligthart, J, Mastik, F, Garg, S, Muller, JE, Wilder, MA, van de Steen, AFW, Regar, E. First‐in‐man clinical use of combined near‐infrared spectroscopy and intravascular ultrasound a potential key to predict distal embolization and no‐reflow? J Am Coll Cardiol 2010, 56:314–314.
83 Libby, P, Aikawa, M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002, 8:1257–1262.
84 Jaffer, FA, Libby, P, Weissleder, R. Molecular and cellular imaging of atherosclerosis: emerging applications. J Am Coll Cardiol 2006, 47:1328–1338.
85 Ni, M, Chen, WQ, Zhang, Y. Animal models and potential mechanisms of plaque destabilisation and disruption. Heart 2009, 95:1393–1398.
86 Nahrendorf, M, Waterman, P, Thurber, G, Groves, K, Rajopadhye, M, Panizzi, P, Marinelli, B, Aikawa, E, Pittet, MJ, Swirski, FK, et al. Hybrid in vivo FMT‐CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol 2009, 29:1444–1451.
87 Ma, LL, Feldman, MD, Tam, JM, Paranjape, AS, Cheruku, KK, Larson, TA, Tam, JO, Ingram, DR, Paramita, V, Villard, JW, et al. Small multifunctional nanoclusters (nanoroses) for targeted cellular imaging and therapy. ACS Nano 2009, 3:2686–2696.
88 Kang, HW, Josephson, L, Petrovsky, A, Weissleder, R, Bogdanov, A , Jr. Magnetic resonance imaging of inducible E‐selectin expression in human endothelial cell culture. Bioconjug Chem 2002, 13:122–127.
89 Kang, HW, Torres, D, Wald, L, Weissleder, R, Bogdanov, AA , Jr. Targeted imaging of human endothelial‐specific marker in a model of adoptive cell transfer. Lab Invest 2006, 86:599–609.
90 Flacke, S, Fischer, S, Scott, MJ, Fuhrhop, RJ, Allen, JS, McLean, M, Winter, P, Sicard, GA, Gaffney, PJ, Wickline, SA, et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001, 104:1280–1285.
91 Peters, D, Kastantin, M, Kotamraju, VR, Karmali, PP, Gujraty, K, Tirrell, M, Ruoslahti, E. Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci U S A 2009, 106:9815–9819.
92 Cormode, DP, Briley‐Saebo, KC, Mulder, WJ, Aguinaldo, JG, Barazza, A, Ma, Y, Fisher, EA, Fayad, ZA. An ApoA‐I mimetic peptide high‐density‐lipoprotein‐based MRI contrast agent for atherosclerotic plaque composition detection. Small 2008, 4:1437–1444.
93 Cormode, DP, Roessl, E, Thran, A, Skajaa, T, Gordon, RE, Schlomka, JP, Fuster, V, Fisher, EA, Mulder, WJ, Proksa, R, et al. Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology 2010, 256:774–782.
94 Frias, JC, Williams, KJ, Fisher, EA, Fayad, ZA. Recombinant HDL‐like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004, 126:16316–16317.
95 Cormode, DP, Skajaa, T, van Schooneveld, MM, Koole, R, Jarzyna, P, Lobatto, ME, Calcagno, C, Barazza, A, Gordon, RE, Zanzonico, P, et al. Nanocrystal core high‐density lipoproteins: a multimodality contrast agent platform. Nano Lett 2008, 8:3715–3723.
96 Tang, TY, Howarth, SP, Miller, SR, Graves, MJ, Patterson, AJ, UK‐I, JM, Li, ZY, Walsh, SR, Brown, AP, Kirkpatrick, PJ, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide‐enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009, 53:2039–2050.
97 Morishige, K, Kacher, DF, Libby, P, Josephson, L, Ganz, P, Weissleder, R, Aikawa, M. High‐resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation 2010, 122:1707–1715.
98 Wang, B, Yantsen, E, Larson, T, Karpiouk, AB, Sethuraman, S, Su, JL, Sokolov, K, Emelianov, SY. Plasmonic intravascular photoacoustic imaging for detection of macrophages in atherosclerotic plaques. Nano Lett 2009, 9:2212–2217.
99 Hyafil, F, Cornily, JC, Feig, JE, Gordon, R, Vucic, E, Amirbekian, V, Fisher, EA, Fuster, V, Feldman, LJ, Fayad, ZA. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 2007, 13:636–641.
100 Hyafil, F, Cornily, JC, Rudd, JH, Machac, J, Feldman, LJ, Fayad, ZA. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage‐specific CT contrast agent N1177: a comparison with 18F‐FDG PET/CT and histology. J Nucl Med 2009, 50:959–965.
101 Harris, TJ, von Maltzahn, G, Lord, ME, Park, JH, Agrawal, A, Min, DH, Sailor, MJ, Bhatia, SN. Protease‐triggered unveiling of bioactive nanoparticles. Small 2008, 4:1307–1312.
102 Schellenberger, E, Rudloff, F, Warmuth, C, Taupitz, M, Hamm, B, Schnorr, J. Protease‐specific nanosensors for magnetic resonance imaging. Bioconjug Chem 2008, 19:2440–2445.
103 Briley‐Saebo, KC, Shaw, PX, Mulder, WJ, Choi, SH, Vucic, E, Aguinaldo, JG, Witztum, JL, Fuster, V, Tsimikas, S, Fayad, ZA. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation‐specific epitopes. Circulation 2008, 117:3206–3215.
104 Briley‐Saebo, KC, Cho, YS, Shaw, PX, Ryu, SK, Mani, V, Dickson, S, Izadmehr, E, Green, S, Fayad, ZA, Tsimikas, S. Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation‐specific epitopes. J Am Coll Cardiol 2011, 57:337–347.
105 van Tilborg, GA, Vucic, E, Strijkers, GJ, Cormode, DP, Mani, V, Skajaa, T, Reutelingsperger, CP, Fayad, ZA, Mulder, WJ, Nicolay, K. Annexin A5‐functionalized bimodal nanoparticles for MRI and fluorescence imaging of atherosclerotic plaques. Bioconjug Chem 2010, 21:1794–1803.
106 Lee, D, Khaja, S, Velasquez‐Castano, JC, Dasari, M, Sun, C, Petros, J, Taylor, WR, Murthy, N. In vivo imaging of hydrogen peroxide with chemiluminescent nanoparticles. Nat Mater 2007, 6:765–769.
107 Lipinski, MJ, Amirbekian, V, Frias, JC, Aguinaldo, JG, Mani, V, Briley‐Saebo, KC, Fuster, V, Fallon, JT, Fisher, EA, Fayad, ZA. MRI to detect atherosclerosis with gadolinium‐containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med 2006, 56:601–610.
108 Amirbekian, V, Lipinski, MJ, Briley‐Saebo, KC, Amirbekian, S, Aguinaldo, JG, Weinreb, DB, Vucic, E, Frias, JC, Hyafil, F, Mani, V, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A 2007, 104:961–966.
109 Nahrendorf, M, Jaffer, FA, Kelly, KA, Sosnovik, DE, Aikawa, E, Libby, P, Weissleder, R. Noninvasive vascular cell adhesion molecule‐1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006, 114:1504–1511.
110 Tsourkas, A, Shinde‐Patil, VR, Kelly, KA, Patel, P, Wolley, A, Allport, JR, Weissleder, R. In vivo imaging of activated endothelium using an anti‐VCAM‐1 magnetooptical probe. Bioconjug Chem 2005, 16:576–581.
111 Kelly, KA, Allport, JR, Tsourkas, A, Shinde‐Patil, VR, Josephson, L, Weissleder, R. Detection of vascular adhesion molecule‐1 expression using a novel multimodal nanoparticle. Circ Res 2005, 96:327–336.
112 Winter, PM, Morawski, AM, Caruthers, SD, Fuhrhop, RW, Zhang, H, Williams, TA, Allen, JS, Lacy, EK, Robertson, JD, Lanza, GM, et al. Molecular imaging of angiogenesis in early‐stage atherosclerosis with
α(v)
β3‐integrin‐targeted nanoparticles. Circulation 2003, 108:2270–2274.
113 Tomokiyo, R, Jinnouchi, K, Honda, M, Wada, Y, Hanada, N, Hiraoka, T, Suzuki, H, Kodama, T, Takahashi, K, Takeya, M. Production, characterization, and interspecies reactivities of monoclonal antibodies against human class A macrophage scavenger receptors. Atherosclerosis 2002, 161:123–132.
114 Guray, U, Erbay, AR, Guray, Y, Yilmaz, MB, Boyaci, AA, Sasmaz, H, Korkmaz, S, Kutuk, E. Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis. Int J Cardiol 2004, 96:235–240.
115 de Boer, OJ, van der Wal, AC, Teeling, P, Becker, AE. Leucocyte recruitment in rupture prone regions of lipid‐rich plaques: a prominent role for neovascularization? Cardiovasc Res 1999, 41:443–449.
116 Brown, MS, Goldstein, JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983, 52:223–261.
117 Nagaoka, K, Takahara, K, Tanaka, K, Yoshida, H, Steinman, RM, Saitoh, S, Akashi‐Takamura, S, Miyake, K, Kang, YS, Park, CG, et al. Association of SIGNR1 with TLR4‐MD‐2 enhances signal transduction by recognition of LPS in gram‐negative bacteria. Int Immunol 2005, 17:827–836.
118 Mulder, WJ, Strijkers, GJ, Briley‐Saboe, KC, Frias, JC, Aguinaldo, JG, Vucic, E, Amirbekian, V, Tang, C, Chin, PT, Nicolay, K, et al. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG‐micelles. Magn Reson Med 2007, 58:1164–1170.
119 Tsimikas, S, Mallat, Z, Talmud, PJ, Kastelein, JJP, Wareham, NJ, Sandhu, MS, Miller, ER, Benessiano, J, Tedgui, A, Witztum, JL, et al. Oxidation‐Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events. J Am Coll Cardiol 2010, 56:946–955.
120 Woo, K, Hong, J, Choi, S, Lee, HW, Ahn, JP, Kim, CS, Lee, SW. Easy synthesis and magnetic properties of iron oxide nanoparticles. Chem Mater 2004, 16:2814–2818.
121 Dubertret, B, Skourides, P, Norris, DJ, Noireaux, V, Brivanlou, AH, Libchaber, A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 2002, 298:1759–1762.
122 Park, J, Joo, J, Kwon, SG, Jang, Y, Hyeon, T. Synthesis of monodisperse spherical nanocrystals. Angew Chem Int Ed 2007, 46:4630–4660.
123 Kelly, KA, Nahrendorf, M, Yu, AM, Reynolds, F, Weissleder, R. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Mol Imaging Biol 2006, 8:201–207.
124 Paranjape, AS, Kuranov, R, Baranov, S, Ma, LL, Villard, JW, Wang, T, Sokolov, KV, Feldman, MD, Johnston, KP, Milner, TE. Depth resolved photothermal OCT detection of macrophages in tissue using nanorose. Biomed Opt Exp 2010, 1:2–16.
125 Yu, SS, Scherer, RL, Ortega, RA, Bell, CS, O`Neil, CP, Hubbell, JA, Giorgio, TD. Enzymatic‐ and temperature‐sensitive controlled release of ultrasmall superparamagnetic iron oxides (USPIOs). J Nanobiotechnol 2011, 9:7.
126 Beumer, JH, Boisdron‐Celle, M, Clarke, W, Courtney, JB, Egorin, MJ, Gamelin, E, Harney, RL, Hammett‐Stabler, C, Lepp, S, Li, Y, et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5‐fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit 2009, 31:688–694.
127 Jaffer, FA, Kim, DE, Quinti, L, Tung, CH, Aikawa, E, Pande, AN, Kohler, RH, Shi, GP, Libby, P, Weissleder, R. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease‐activatable fluorescence sensor. Circulation 2007, 115:2292–2298.
128 Sukhova, GK, Shi, GP, Simon, DI, Chapman, HA, Libby, P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998, 102:576–583.
129 Rodgers, KJ, Watkins, DJ, Miller, AL, Chan, PY, Karanam, S, Brissette, WH, Long, CJ, Jackson, CL. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2006, 26:851–856.
130 Li, W, Yuan, XM. Increased expression and translocation of lysosomal cathepsins contribute to macrophage apoptosis in atherogenesis. Ann N Y Acad Sci 2004, 1030:427–433.
131 Tung, CH, Bredow, S, Mahmood, U, Weissleder, R. Preparation of a cathepsin D sensitive near‐infrared fluorescence probe for imaging. Bioconjug Chem 1999, 10:892–896.
132 Lakowicz, JR. Principles of Fluorescence Spectroscopy.
3rd ed. New York:
Springer; 2006.
133 Deguchi, JO, Aikawa, M, Tung, CH, Aikawa, E, Kim, DE, Ntziachristos, V, Weissleder, R, Libby, P. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006, 114:55–62.
134 Chen, J, Tung, CH, Mahmood, U, Ntziachristos, V, Gyurko, R, Fishman, MC, Huang, PL, Weissleder, R. In vivo imaging of proteolytic activity in atherosclerosis. Circulation 2002, 105:2766–2771.
135 Altinoglu, EI, Adair, JH. Near infrared imaging with nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010, 2:461–477.
136 Chang, E, Miller, JS, Sun, J, Yu, WW, Colvin, VL, Drezek, R, West, JL. Protease‐activated quantum dot probes. Biochem Biophys Res Commun 2005, 334:1317–1321.
137 Sun, J, Fu, K, Zhu, M‐Q, Bickford, L, Post, E, Drezek, R. Near‐infrared quantum dot contrast agents for fluorescence tissue imaging: a phantom study. Curr Nanosci 2009, 5:160–166.
138 Smith, AM, Nie, S. Bright and compact alloyed quantum dots with broadly tunable near‐infrared absorption and fluorescence spectra through mercury cation exchange. J Am Chem Soc 2010, 133:24–26.
139 Ma, Q, Su, X. Near‐infrared quantum dots: synthesis, functionalization and analytical applications. Analyst 2010, 135:1867–1877.
140 Kim, S, Lim, YT, Soltesz, EG, De Grand, AM, Lee, J, Nakayama, A, Parker, JA, Mihaljevic, T, Laurence, RG, Dor, DM, et al. Near‐infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 2004, 22:93–97.
141 Bailey, RE, Strausburg, JB, Nie, S. A new class of far‐red and near‐infrared biological labels based on alloyed semiconductor quantum dots. J Nanosci Nanotechnol 2004, 4:569–574.
142 Hauck, TS, Anderson, RE, Fischer, HC, Newbigging, S, Chan, WC. In vivo quantum‐dot toxicity assessment. Small 2010, 6:138–144.
143 Chang, E, Thekkek, N, Yu, WW, Colvin, VL, Drezek, R. Evaluation of quantum dot cytotoxicity based on intracellular uptake. Small 2006, 2:1412–1417.
144 Sewell, SL, Giorgio, TD. Synthesis and enzymatic cleavage of dual‐ligand quantum dots. Mater Sci Eng C Mater Biol Appl 2009, 29:1428–1432.
145 Smith, R, Sewell, SL, Giorgio, TD. Proximity‐activated nanoparticles: in vitro performance of specific structural modification by enzymatic cleavage. Int J Nanomed 2008, 3:95–103.
146 Sewell, SL, Giorgio, TD. Surface functionalized nanoparticles for proximity‐activated detection and imaging of breast cancer. Cancer Res 2009, 69:348s.
147 Guyton, AC, Hall, JE. Textbook of Medical Physiology,
11th ed. Philadelphia:
Elsevier Saunders; 2006.
148 Brannon‐Peppas, L, Blanchette, JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004, 56:1649–1659.
149 Storm, G, Belliot, SO, Daemen, T, Lasic, DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Delivery Rev 1995, 17:31–48.
150 Li, SD, Huang, L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta 2009, 1788:2259–2266.
151 Kirkland‐York, S, Zhang, Y, Smith, AE, York, AW, Huang, F, McCormick, CL. Tailored design of Au nanoparticle‐siRNA carriers utilizing reversible addition‐fragmentation chain transfer polymers. Biomacromolecules 2010, 11:1052–1059.
152 Wickline, SA, Neubauer, AM, Winter, PM, Caruthers, SD, Lanza, GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging 2007, 25:667–680.
153 Maeda, H, Wu, J, Sawa, T, Matsumura, Y, Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Contr Rel 2000, 65:271–284.
154 Davis, ME, Zuckerman, JE, Choi, CH, Seligson, D, Tolcher, A, Alabi, CA, Yen, Y, Heidel, JD, Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067–1070.
155 Weissleder, R, Kelly, K, Sun, EY, Shtatland, T, Josephson, L. Cell‐specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 2005, 23:1418–1423.
156 Senpan, A, Caruthers, SD, Rhee, I, Mauro, NA, Pan, D, Hu, G, Scott, MJ, Fuhrhop, RW, Gaffney, PJ, Wickline, SA, et al. Conquering the dark side: colloidal iron oxide nanoparticles. Acs Nano 2009, 3:3917–3926.
157 Erogbogbo, F, Yong, K‐T, Roy, I, Xu, G, Prasad, PN, Swihart, MT. Biocompatible luminescent silicon quantum dots for imaging of cancer cells. Acs Nano 2008, 2:873–878.
158 McIntyre, JO, Scherer, RL, Matrisian, LM. Near‐infrared optical proteolytic beacons for in vivo imaging of matrix metalloproteinase activity. Methods Mol Biol 2010, 622:279–304.
159 Scherer, RL, VanSaun, MN, McIntyre, JO, Matrisian, LM. Optical imaging of matrix metalloproteinase‐7 activity in vivo using a proteolytic nanobeacon. Mol Imaging 2008, 7:118–131.
160 Tsimikas, S, Willerson, JT, Ridker, PM. C‐reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006, 47:C19–C31.
161 Vasan, RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335–2362.
162 Hirsch, LR, Halas, NJ, West, JL. Whole‐blood immunoassay facilitated by gold nanoshell‐conjugate antibodies. Methods Mol Biol 2005, 303:101–111.
163 Soman, CP, Giorgio, TD. Quantum dot self‐assembly for protein detection with sub‐picomolar sensitivity. Langmuir 2008, 24:4399–4404.
164 Kim, KS, Park, JK. Magnetic force‐based multiplexed immunoassay using superparamagnetic nanoparticles in microfluidic channel. Lab Chip 2005, 5:657–664.
165 Perez, JM, Josephson, L, O`Loughlin, T, Hogemann, D, Weissleder, R. Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol 2002, 20:816–820.
166 Hirsch, LR, Jackson, JB, Lee, A, Halas, NJ, West, JL. A whole blood immunoassay using gold nanoshells. Anal Chem 2003, 75:2377–2381.
167 Blinka, E, Loeffler, K, Hu, Y, Gopal, A, Hoshino, K, Lin, K, Liu, X, Ferrari, M, Zhang, JX. Enhanced microcontact printing of proteins on nanoporous silica surface. Nanotechnology 2010, 21:415302.
168 Agrawal, A, Sathe, T, Nie, S. Single‐bead immunoassays using magnetic microparticles and spectral‐shifting quantum dots. J Agric Food Chem 2007, 55:3778–3782.
169 Bulte, JWM, Modo, MMJ, Perez, JM, Kaittanis, C. %22Magnetic nanosensors for probing molecular interactions.%22 In: Ferrari, M, ed. Nanoparticles in Biomedical Imaging, Vol 102. New York:
Springer; 2008, 183–197.
170 Ibraimi, F, Kriz, D, Lu, M, Hansson, L‐O, Kriz, K. Rapid one‐step whole blood C‐reactive protein magnetic permeability immunoassay with monoclonal antibody conjugated nanoparticles as superparamagnetic labels and enhanced sedimentation. Anal Bioanal Chem 2006, 384:651–657.
171 Ng, AH, Uddayasankar, U, Wheeler, AR. Immunoassays in microfluidic systems. Anal Bioanal Chem 2010, 397:991–1007.
172 Jokerst, JV, Raamanathan, A, Christodoulides, N, Floriano, PN, Pollard, AA, Simmons, GW, Wong, J, Gage, C, Furmaga, WB, Redding, SW, et al. Nano‐bio‐chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels. Biosens Bioelectron 2009, 24:3622–3629.
173 Sia, SK, Whitesides, GM. Microfluidic devices fabricated in poly(dimethylsiloxane) for biological studies. Electrophoresis 2003, 24:3563–3576.
174 McClain, MA, Culbertson, CT, Jacobson, SC, Ramsey, JM. Flow cytometry of
Escherichia coli on microfluidic devices. Anal Chem 2001, 73:5334–5338.
175 Wlodkowic, D, Faley, S, Zagnoni, M, Wikswo, JP, Cooper, JM. Microfluidic single‐cell array cytometry for the analysis of tumor apoptosis. Anal Chem 2009, 81:5517–5523.
176 Adams, ML, Enzelberger, M, Quake, S, Scherer, A. Microfluidic integration on detector arrays for absorption and fluorescence micro‐spectrometers. Sensors Actuat A Phys 2003, 104:25–31.
177 Haun, JB, Yoon, TJ, Lee, H, Weissleder, R. Magnetic nanoparticle biosensors. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010, 2:291–304.
178 Lee, H, Sun, E, Ham, D, Weissleder, R. Chip‐NMR biosensor for detection and molecular analysis of cells. Nat Med 2008, 14:869–874.
179 Chastek, TQ, Beers, KL, Amis, EJ. Miniaturized dynamic light scattering instrumentation for use in microfluidic applications. Rev Sci Instrum 2007, 78:072201.
180 Chastek, TQ, Iida, K, Amis, EJ, Fasolka, MJ, Beers, KL. A microfluidic platform for integrated synthesis and dynamic light scattering measurement of block copolymer micelles. Lab Chip 2008, 8:950–957.
181 Soman, C, Giorgio, T. Sensitive and multiplexed detection of proteomic antigens via quantum dot aggregation. Nanomed: Nanotechnol Biol Med 2009, 5:402–409.
182 Wyatt, PJ. Light‐Scattering and the absolute characterization of macromolecules. Anal Chim Acta 1993, 272:1–40.
183 Oden, M, Mirabal, Y, Epstein, M, Richards‐Kortum, R. Engaging undergraduates to solve global health challenges: a new approach based on bioengineering design. Ann Biomed Eng 2010, 38:3031–3041.
184 Bruls, DM, Evers, TH, Kahlman, JAH, van Lankvelt, PJW, Ovsyanko, M, Pelssers, EGM, Schleipen, JJHB, de Theije, FK, Verschuren, CA, van der Wijk, T, et al. Rapid integrated biosensor for multiplexed immunoassays based on actuated magnetic nanoparticles. Lab Chip 2009, 9:3504–3510.
185 Floriano, PN, Christodoulides, N, Miller, CS, Ebersole, JL, Spertus, J, Rose, BG, Kinane, DF, Novak, MJ, Steinhubl, S, Acosta, S, et al. Use of saliva‐based nano‐biochip tests for acute myocardial infarction at the point of care: a feasibility study. Clin Chem 2009, 55:1530–1538.
186 Lavigne, JJ, Savoy, S, Clevenger, MB, Ritchie, JE, McDoniel, B, Yoo, S‐J, Anslyn, EV, McDevitt, JT, Shear, JB, Neikirk, D. Solution‐based analysis of multiple analytes by a sensor array: toward the development of an “electronic tongue”. J Am Chem Soc 1998, 120:6429–6430.
187 Buch, M, Rishpon, J. An electrochemical immunosensor for C‐reactive protein based on multi‐walled carbon nanotube‐modified electrodes. Electroanalysis 2008, 20:2592–2594.
188 Wang, J. Carbon‐nanotube based electrochemical biosensors: a review. Electroanalysis 2005, 17:7–14.
189 Gruntzig, AR, Senning, A, Siegenthaler, WE. Nonoperative dilatation of coronary‐artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979, 301:61–68.
190 de Feyter, PJ, de Jaegere, PP, Serruys, PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994, 127:643–651.
191 Sigwart, U, Urban, P, Golf, S, Kaufmann, U, Imbert, C, Fischer, A, Kappenberger, L. Emergency stenting for acute occlusion after coronary balloon angioplasty. Circulation 1988, 78:1121–1127.
192 Sigwart, U, Puel, J, Mirkovitch, V, Joffre, F, Kappenberger, L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987, 316:701–706.
193 Moliterno, DJ. Healing achilles—sirolimus versus paclitaxel. N Engl J Med 2005, 353:724–727.
194 Karas, SP, Gravanis, MB, Santoian, EC, Robinson, KA, Anderberg, KA, King, SB , 3rd. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 1992, 20:467–474.
195 Gordon, PC, Gibson, CM, Cohen, DJ, Carrozza, JP, Kuntz, RE, Baim, DS. Mechanisms of restenosis and redilation within coronary stents—quantitative angiographic assessment. J Am Coll Cardiol 1993, 21:1166–1174.
196 Hoffmann, R, Mintz, GS, Dussaillant, GR, Popma, JJ, Pichard, AD, Satler, LF, Kent, KM, Griffin, J, Leon, MB. Patterns and mechanisms of in‐stent restenosis. a serial intravascular ultrasound study. Circulation 1996, 94:1247–1254.
197 Babapulle, MN, Joseph, L, Belisle, P, Brophy, JM, Eisenberg, MJ. A hierarchical Bayesian meta‐analysis of randomised clinical trials of drug‐eluting stents. Lancet 2004, 364:583–591.
198 Stone, GW, Ellis, SG, Cox, DA, Hermiller, J, O`Shaughnessy, C, Mann, JT, Turco, M, Caputo, R, Bergin, P, Greenberg, J, et al. One‐year clinical results with the slow‐release, polymer‐based, paclitaxel‐eluting TAXUS stent: the TAXUS‐IV trial. Circulation 2004, 109:1942–1947.
199 Moses, JW, Leon, MB, Popma, JJ, Fitzgerald, PJ, Holmes, DR, O`Shaughnessy, C, Caputo, RP, Kereiakes, DJ, Williams, DO, Teirstein, PS, et al. Sirolimus‐eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315–1323.
200 Nordmann, AJ, Briel, M, Bucher, HC. Mortality in randomized controlled trials comparing drug‐eluting vs. bare metal stents in coronary artery disease: a meta‐analysis. Eur Heart J 2006, 27:2784–2814.
201 Camenzind, E, Steg, PG, Wijns, W. Stent thrombosis late after implantation of first‐generation drug‐eluting stents: a cause for concern. Circulation 2007, 115:1440–1455, discussion 1455.
202 Lagerqvist, B, James, SK, Stenestrand, U, Lindback, J, Nilsson, T, Wallentin, L. Long‐term outcomes with drug‐eluting stents versus bare‐metal stents in Sweden. N Engl J Med 2007, 356:1009–1019.
203 Kastrati, A, Dibra, A, Eberle, S, Mehilli, J, Suarez de Lezo, J, Goy, JJ, Ulm, K, Schomig, A. Sirolimus‐eluting stents vs paclitaxel‐eluting stents in patients with coronary artery disease: meta‐analysis of randomized trials. JAMA 2005, 294:819–825.
204 Niccoli, G, Montone, RA, Ferrante, G, Crea, F. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol 2010, 56:1783–1793.
205 Kastrati, A, Mehilli, J, Dirschinger, J, Dotzer, F, Schuhlen, H, Neumann, FJ, Fleckenstein, M, Pfafferott, C, Seyfarth, M, Schomig, A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR‐STEREO) trial. Circulation 2001, 103:2816–2821.
206 Pache, J, Kastrati, A, Mehilli, J, Schuhlen, H, Dotzer, F, Hausleiter, J, Fleckenstein, M, Neumann, FJ, Sattelberger, U, Schmitt, C, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR‐STEREO‐2) trial. J Am Coll Cardiol 2003, 41:1283–1288.
207 Kereiakes, DJ, Cox, DA, Hermiller, JB, Midei, MG, Bachinsky, WB, Nukta, ED, Leon, MB, Fink, S, Marin, L, Lansky, AJ. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 2003, 92: 463–466.
208 Stone, GW, Rizvi, A, Newman, W, Mastali, K, Wang, JC, Caputo, R, Doostzadeh, J, Cao, S, Simonton, CA, Sudhir, K, et al. Everolimus‐eluting versus paclitaxel‐eluting stents in coronary artery disease. New Engl J Med 2010, 362:1663–1674.
209 Byrne, RA, Kufner, S, Tiroch, K, Massberg, S, Laugwitz, KL, Birkmeier, A, Schulz, S, Mehilli, J. Randomised trial of three rapamycin‐eluting stents with different coating strategies for the reduction of coronary restenosis: 2‐year follow‐up results. Heart 2009, 95: 1489–1494.
210 Byrne, RA, Mehilli, J, Iijima, R, Schulz, S, Pache, J, Seyfarth, M, Schomig, A, Kastrati, A. A polymer‐free dual drug‐eluting stent in patients with coronary artery disease: a randomized trial vs. polymer‐based drug‐eluting stents. Eur Heart J 2009, 30: 923–931.
211 Tamai, H, Igaki, K, Kyo, E, Kosuga, K, Kawashima, A, Matsui, S, Komori, H, Tsuji, T, Motohara, S, Uehata, H. Initial and 6‐month results of biodegradable poly‐l‐lactic acid coronary stents in humans. Circulation 2000, 102:399–404.
212 Tsuji, T, Tamai, H, Igaki, K, Hsu, Y‐S, Kosuga, KMO, Nakamura, T, Fujita, S. Four‐year follow‐up of the biodegradable stent (IGAKI‐TAMAI Stent). Circ J 2004, 68:135.
213 Erbel, R, Di Mario, C, Bartunek, J, Bonnier, J, de Bruyne, B, Eberli, FR, Erne, P, Haude, M, Heublein, B, Horrigan, M, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non‐randomised multicentre trial. Lancet 2007, 369:1869–1875.
214 Ormiston, JA, Serruys, PW, Regar, E, Dudek, D, Thuesen, L, Webster, MW, Onuma, Y, Garcia‐Garcia, HM, McGreevy, R, Veldhof, S. A bioabsorbable everolimus‐eluting coronary stent system for patients with single de‐novo coronary artery lesions (ABSORB): a prospective open‐label trial. Lancet 2008, 371: 899–907.
215 Serruys, PW, Ormiston, JA, Onuma, Y, Regar, E, Gonzalo, N, Garcia‐Garcia, HM, Nieman, K, Bruining, N, Dorange, C, Miquel‐Hebert, K, et al. A bioabsorbable everolimus‐eluting coronary stent system (ABSORB): 2‐year outcomes and results from multiple imaging methods. Lancet 2009, 373:897–910.
216 Jiang, W‐W, Su, S‐H, Eberhart, RC, Tang, L. Phagocyte responses to degradable polymers. J Biomed Mater Res A 2007, 82A:492–497.
217 Ramcharitar, S, Gonzalo, N, van Geuns, RJ, Garcia‐Garcia, HM, Wykrzykowska, JJ, Ligthart, JMR, Regar, E, Serruys, PW. First case of stenting of a vulnerable plaque in the SECRITT I trial—the dawn of a new era? Nat Rev Cardiol 2009, 6:374–378.
218 O`Brien, B, Carroll, W. The evolution of cardiovascular stent materials and surfaces in response to clinical drivers: A review. Acta Biomater 2009, 5: 945–958.
219 Virmani, R, Guagliumi, G, Farb, A, Musumeci, G, Grieco, N, Motta, T, Mihalcsik, L, Tespili, M, Valsecchi, O, Kolodgie, FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus‐eluting stent should we be cautious? Circulation 2004, 109:701–705.
220 Kuchulakanti, PK, Chu, WW, Torguson, R, Ohlmann, P, Rha, SW, Clavijo, LC, Kim, SW, Bui, A, Gevorkian, N, Xue, ZY, et al. Correlates and long‐term outcomes of angiographically proven stent thrombosis with sirolimus‐ and paclitaxel‐eluting stents. Circulation 2006, 113:1108–1113.
221 Joner, M, Finn, AV, Farb, A, Mont, EK, Kolodgie, FD, Ladich, E, Kutys, R, Skorija, K, Gold, HK, Virmani, R. Pathology of drug‐eluting stents in humans—delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193–202.
222 Tada, DB, Singh, S, Nagesha, D, Jost, E, Levy, CO, Gultepe, E, Cormack, R, Makrigiorgos, GM, Sridhar, S. Chitosan film containing Poly(D,L‐Lactic‐Co‐glycolic acid) nanoparticles: a platform for localized dual‐drug release. Pharma Res 2010, 27:1738–1745.
223 Jayagopal, A, Sussman, EM, Shastri, VP. Functionalized solid lipid nanoparticles for transendothelial delivery. IEEE Trans Nanobiosci 2008, 7:28–34.
224 Jin, C, Bai, L, Wu, H, Song, W, Guo, GZ, Dou, KF. Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. Pharma Res 2009, 26:1776–1784.
225 Ranganath, SH, Kee, I, Krantz, WB, Chow, PKH, Wang, CH. Hydrogel matrix entrapping PLGA‐paclitaxel microspheres: drug delivery with near zero‐order release and implantability advantages for malignant brain tumour chemotherapy. Pharma Res 2009, 26:2101–2114.
226 Bhargava, B, Reddy, NK, Karthikeyan, G, Raju, R, Mishra, S, Singh, S, Waksman, R, Virmani, R, Somaraju, B. A novel paclitaxel‐eluting porous carbon‐carbon nanoparticle coated, nonpolymeric cobalt‐chromium stent: evaluation in a porcine model. Cathet Cardiovasc Intervent 2006, 67:698–702.
227 Kushwaha, M, Anderson, JM, Bosworth, CA, Andukuri, A, Minor, WP, Lancaster, JR, Anderson, PG, Brott, BC, Jun, HW. A nitric oxide releasing, self assembled peptide amphiphile matrix that mimics native endothelium for coating implantable cardiovascular devices. Biomaterials 2010, 31:1502–1508.
228 Andukuri, A, Minor, WP, Kushwaha, M, Anderson, JM, Jun, HW. Effect of endothelium mimicking self‐assembled nanomatrices on cell adhesion and spreading of human endothelial cells and smooth muscle cells. Nanomed Nanotechnol Biol Med 2010, 6: 289–297.
229 Decher, G. Fuzzy nanoassemblies: toward layered polymeric multicomposites. Science 1997, 277: 1232–1237.
230 Soike, T, Streff, AK, Guan, CX, Ortega, R, Tantawy, M, Pino, C, Shastri, VP. Engineering a material surface for drug delivery and imaging using layer‐by‐layer assembly of functionalized nanoparticles. Adv Mater 2010, 22:1992.
231 Weber, N, Pesnell, A, Bolikal, D, Zeltinger, J, Kohn, J. Viscoelastic properties of fibrinogen adsorbed to the surface of biomaterials used in blood‐contacting medical devices. Langmuir 2007, 23: 3298–3304.
232 Otsuka, M, Tanimoto, S, Sianos, G, Kukreja, N, Weustink, AC, Serruys, PW, De Feyter, PJ. “Radio‐lucent” and “radio‐opaque” coronary stents characterized by multislice computed tomography. Int J Cardiol 2009, 132:E8–E10.
233 Luscher, TF, Steffel, J, Eberli, FR, Joner, M, Nakazawa, G, Tanner, FC, Virmani, R. Drug‐eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007, 115: 1051–1058.
234 Daemen, J, Wenaweser, P, Tsuchida, K, Abrecht, L, Vaina, S, Morger, C, Kukreja, N, Juni, P, Sianos, G, Hellige, G, et al. Early and late coronary stent thrombosis of sirolimus‐eluting and paclitaxel‐eluting stents in routine clinical practice: data from a large two‐institutional cohort study. Lancet 2007, 369: 667–678.
235 Peng, L, Eltgroth, ML, LaTempa, TJ, Grimes, CA, Desai, TA. The effect of TiO
2 nanotubes on endothelial function and smooth muscle proliferation. Biomaterials 2009, 30:1268–1272.
236 Lu, J, Rao, MP, MacDonald, NC, Khang, D, Webster, TJ. Improved endothelial cell adhesion and proliferation on patterned titanium surfaces with rationally designed, micrometer to nanometer features. Acta Biomater 2008, 4:192–201.
237 Miller, DC, Thapa, A, Haberstroh, KM, Webster, TJ. Endothelial and vascular smooth muscle cell function on poly(lactic‐co‐glycolic acid) with nano‐structured surface features. Biomaterials 2004, 25: 53–61.
238 Fine, E, Zhang, L, Fenniri, H, Webster, TJ. Enhanced endothelial cell functions on rosette nanotube‐coated titanium vascular stents. Int J Nanomed 2009, 4:91–97.
239 Kipshidze, N, Dangas, G, Tsapenko, M, Moses, J, Leon, MB, Kutryk, M, Serruys, P. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 2004, 44:733–739.
240 Lu, J, Khang, D, Webster, TJ. Greater endothelial cell responses on submicron and nanometer rough titanium surfaces. J Biomed Mater Res A 2010, 94A:1042–1049.
241 Khang, D, Kim, SY, Liu‐Snyder, P, Palmore, GTR, Durbin, SM, Webster, TJ. Enhanced fibronectin adsorption on carbon nanotube/poly(carbonate) urethane: independent role of surface nano‐roughness and associated surface energy. Biomaterials 2007, 28: 4756–4768.
242 Loya, MC, Brammer, KS, Choi, C, Chen, LH, Jin, SH. Plasma‐induced nanopillars on bare metal coronary stent surface for enhanced endothelialization. Acta Biomater 2010, 6:4589–4595.
243 Brammer, KS, Choi, C, Oh, S, Cobb, CJ, Connelly, LS, Loya, M, Kong, SD, Jin, S. Antibiofouling, sustained antibiotic release by Si nanowire templates. Nano Lett 2009, 9:3570–3574.
244 Samaroo, HD, Lu, J, Webster, TJ. Enhanced endothelial cell density on NiTi surfaces with sub‐macron to nanometer roughness. Int J Nanomed 2008, 3: 75–82.
245 Wieneke, H, Dirsch, O, Sawitowski, T, Gu, YL, Brauer, H, Dahmen, U, Fischer, A, Wnendt, S, Erbel, R. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Cathet Cardiovasc Intervent 2003, 60:399–407.